Umoja

CAR‑T immunotherapy — in which a patient’s own T cells are removed from their body, repro­grammed in the lab to target and destroy cancer cells, and then rein­tro­duced — has saved the lives of thousands of leukemia, lymphoma, and myeloma patients. But the procedure is slow, expensive, and hazardous. Umoja is developing a vector that delivers RNA instruc­tions for the needed cancer-targeting receptors directly into the bloodstream, potentially lowering the risks and costs of cancer treatment and generating lasting remissions.